Pfizer will draw on the expertise of Citi analyst Andrew Baum when it comes to portfolio management and capital deployment, naming him chief strategy and innovation office
Shah Capital has stepped up its campaign for change at vaccine producer Novavax, lobbying against the re-election of three directors and executive pay packages in a letter
UK start-up George Medicines has named Mark Mallon as its new chief executive, who will oversee the company as it tries to get its triple therapy for high blood pressure o
Novartis has posted a healthy rise in sales and profits in the first full quarter since it separated from Sandoz and proposed former Bristol Myers Squibb’s chief executive
BenevolentAI is embarking on another round of job losses, closing its US office, and shelving its software-as-a-service business to extend its cash reserves into the third
Shah Capital has fired a broadside at the management team of Novavax, seeking a change in leadership at the vaccine company and the appointment of two handpicked directors
Legislation that would restrict US organisations from contracting with some Chinese biotech providers has been passed by a House of Representatives committee, moving close
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.